Omalizumab in eosinophilic granulomatosis with polyangiitis: friend or foe? A systematic literature review.
Clin Exp Rheumatol
; 38 Suppl 124(2): 214-220, 2020.
Article
em En
| MEDLINE
| ID: mdl-32083537
ABSTRACT
OBJECTIVES:
To systematically evaluate, through a Medline search, the role of omalizumab in eosinophilic granulomatosis with polyangiitis (EGPA).METHODS:
A systematic review was performed with the following inclusion criteria original articles and case reports written in English and reporting an association between omalizumab and EGPA.RESULTS:
We found 18 papers on EGPA (14 case reports, 3 retrospective cohort studies, 1 prospective cohort study). Omalizumab showed to be effective as corticosteroid-sparing agent in EGPA patients with severe asthmatic manifestations. On the contrary, conflicting results concerned its use in refractory forms of EGPA. Plausible is the increased risk of EGPA onset among asthmatic patients treated with omalizumab, probably related to steroid reduction, even if it cannot be excluded that omalizumab might be occasionally directly involved in the pathogenesis.CONCLUSIONS:
Our findings support the use of omalizumab in selected forms of EGPA, but caution in the tapering of corticosteroids is also recommended. Quality of evidence is limited, as the source of information was mainly case reports. Clinical trials are required in order to evaluate the role of omalizumab in EGPA and to ascertain the risk of asthmatic patients given omalizumab to develop EGPA.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Asma
/
Síndrome de Churg-Strauss
/
Granulomatose com Poliangiite
/
Omalizumab
Tipo de estudo:
Observational_studies
/
Risk_factors_studies
/
Systematic_reviews
Limite:
Humans
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article